Oryzon Genomics S.a.

Oncostellae, S.l.

Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii

Guido Kurz

Alberto Ortega Muñoz

Matthew Colin Thor Fyfe

Marc Martinell Pedemonte

Julio Cesar Castro Palomino Laria

Nuria Valls Vidal

Maria De Los Àngeles Estiarte Martinez

Joaquín Pastor Fernández

Juan Camacho Gómez

María De Los Ángeles Estiarte Martínez

Sonia Martínez Gonzalez

Joaquin Pastor Fernandez

Alberto Ortega MUÑOZ

Juan Camacho GÓMEZ

María De Los ÁNgeles Estiarte MARTÍNEZ

The present invention relates to novel dihydropyridine derivatives of formula (I): as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of androgen receptor and/or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases, cachexia, Cushing's syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.

Androgen receptor and glucocorticoid receptor modulators

The present invention relates to novel 11-oxo-11H-pyrido[2,1-b]quinazoline-6-carboxamide derivatives as potent inhibitors of protein kinase, to pharmaceutical compositions containing them and to the use of said compounds for the manufacture of a drug for the treatment of diseases or pathological diseases that can be improved by inhibiting protein kinase.

Pyridoquinazoline derivatives useful as protein kinase inhibitors

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. 

(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. 

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. 

Growing community of inventors

Barcelona, Spain

Guido Kurz